Empowering Oncology Decisions
DiagnoCure is a life sciences company that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions.
Special Announcement
FDA APPROVES PROGENSA PCA3 ASSAY
News
- May 1, 2012 - DiagnoCure Issues Statement on Acquisition of Gen-Probe by Hologic

- March 30, 2012 - DiagnoCure 2012 First Quarter Results

Events
|
0.70
0.00
|
Open: 0.70 $CAN.
Quotes are delayed.
|

